Swiss double Covid vaccine order from Pfizer/BioNTech
The Swiss government has signed a new deal with Pfizer/BioNTech for another three million vaccine doses, bringing the total number of doses ordered from five companies to nearly 36 million.
The additional doses will be delivered to Switzerland in April, according to the government. When announcing the “good news”, health minister Alain Berset tweeted that “one million (doses) will already be available in the cantons in April, May and June”.
This comes amid concerns about the slow pace of the vaccine rollout. To date, only 1.3 million doses have been delivered and around 3.8% of the population has been fully vaccinated. As a comparison, in Israel, which has about the same population as Switzerland, more than 40% of the population is fully vaccinated.
During a press conference yesterday, Nora Kronig, deputy director of the Federal Office of Public Health, said vaccinations were still progressing according to plan. “We are still confident that by the end of June we will be able to vaccinate anyone who wants to,” Kronig told reporters.
Spreading its purchases
Switzerland has so far bought more than 35 million doses for its population of 8.6 million. These doses are from five manufacturers: Moderna (13.5 million doses), Pfizer/BioNTech (now around 6 million), Oxford/AstraZeneca (around 5.3 million), Curevac (5 million) and Novavax (6 million).
In a statementExternal link, the government said “given that production and availability of vaccines are subject to such great uncertainty, the federal government continues to look into different vaccine technologies from different vaccine manufacturers”. However, it is focusing on mRNA vaccines because they are “proving to be highly effective and well tolerated”. Four out of the five vaccines ordered are mRNA-based.
So far, only the Pfizer and Moderna vaccines have been approved by the Swiss medical regulator Swissmedic. CureVac and Novavax have not yet filed for approval and Oxford/AstraZeneca’s vaccine is still being reviewed. Swissmedic has said that based on the available data, the safety, efficacy and quality of the vaccine could not be conclusively evaluated. It is still awaiting results of large-scale clinical trials from Oxford/AstraZeneca.
This content was published on
Viola Amherd has expressed her “deep shock” at the assassination attempt on Slovakian Prime Minister Robert Fico on Wednesday.
This content was published on
A man injured half a dozen people with knives, two of them seriously, before being arrested on Wednesday in northern Switzerland.
Switzerland to introduce flight passenger database
This content was published on
Switzerland plans to introduce a flight passenger database to collect and process personal data in a bid to combat terrorism and serious crime.
Government plans to invest over CHF16bn in Swiss rail network
This content was published on
The federal government intends to invest CHF16.4 billion ($18.1 billion) in railway infrastructure between 2025 and 2028, CHF2 billion more than for the current period.
Swiss to vote on pension reform and biodiversity in September
This content was published on
Swiss citizens will vote on occupational pension schemes and a biodiversity initiative on September 22, the Federal Council announced on Wednesday.
Ukraine peace talks: 50 countries have confirmed participation
This content was published on
To date, 50 countries out 160 invited delegations have confirmed they will attend the Ukraine peace conference, held in central Switzerland in mid-June, according to Swiss public radio, RTS.
Federer-backed On boosts forecast after sneaker demand rises
This content was published on
Swiss footwear company On Holding AG posted strong first-quarter revenue, boosted by demand for its running shoes and new line of training apparel.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 vaccine: Why we still have a long wait ahead
This content was published on
Countries have started rolling out a Covid-19 vaccine, but it will likely take years to manufacture doses at the scale needed to reach the masses.
This content was published on
Switzerland will be affected by the temporary delay to the Pfizer-BioNTech Covid-19 vaccine in Europe, the Swiss health authorities have confirmed.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.